Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Xinjian Yu

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
Molecular Therapy. Methods & Clinical Development|December 13, 2021
Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALLBiping Deng, Jing Pan, Zhaoli Liu, et al.
Blood|July 25, 2025
Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trialJing Pan, Liping Zhao, Yibing Zhang, et al.
Blood Advances|September 14, 2021
Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphomaYing Liu, Biping Deng, Bo Hu, et al.
Journal of Affective Disorders|June 2, 2024
Graph convolutional network with attention mechanism improve major depressive depression diagnosis based on plasma biomarkers and neuroimaging dataChaonan Jiang, Bo Lin, Xinyi Ye, et al.
Nature Medicine|October 1, 2024
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trialJing Pan, Yue Tan, Lingling Shan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I TrialJing Pan, Yue Tan, Guoling Wang, et al.
The Lancet. Oncology|October 20, 2023
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 studyJing Pan, Kaiting Tang, Yuechen Luo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 8, 2024
Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trialLiping Zhao, Chuo Li, Shiyu Zuo, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2025
Differentiation Stage Predicts Radiosensitivity in Mesenchymal-Like Pancreatic CancerTingshi Su, Xinjian Yu, Mojtaba Hoseini-Ghahfarokhi, et al.
Nature Communications|July 22, 2024
C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trialShiyu Zuo, Chuo Li, Xiaolei Sun, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
Molecular Therapy. Methods & Clinical Development|December 13, 2021
Peripheral leukemia burden at time of apheresis negatively affects the clinical efficacy of CART19 in refractory or relapsed B-ALLBiping Deng, Jing Pan, Zhaoli Liu, et al.
Blood|July 25, 2025
Donor-derived CD7 CAR T cells for pediatric and adult relapsed/refractory T-ALL/LBL: a phase 2 trialJing Pan, Liping Zhao, Yibing Zhang, et al.
Blood Advances|September 14, 2021
Sequential different B-cell antigen-targeted CAR T-cell therapy for pediatric refractory/relapsed Burkitt lymphomaYing Liu, Biping Deng, Bo Hu, et al.
Journal of Affective Disorders|June 2, 2024
Graph convolutional network with attention mechanism improve major depressive depression diagnosis based on plasma biomarkers and neuroimaging dataChaonan Jiang, Bo Lin, Xinyi Ye, et al.
Nature Medicine|October 1, 2024
Allogeneic CD5-specific CAR-T therapy for relapsed/refractory T-ALL: a phase 1 trialJing Pan, Yue Tan, Lingling Shan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 29, 2021
Donor-Derived CD7 Chimeric Antigen Receptor T Cells for T-Cell Acute Lymphoblastic Leukemia: First-in-Human, Phase I TrialJing Pan, Yue Tan, Guoling Wang, et al.
The Lancet. Oncology|October 20, 2023
Sequential CD19 and CD22 chimeric antigen receptor T-cell therapy for childhood refractory or relapsed B-cell acute lymphocytic leukaemia: a single-arm, phase 2 studyJing Pan, Kaiting Tang, Yuechen Luo, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|September 8, 2024
Autologous CD7 CAR-T cells generated without T cell pre-selection in pediatric patients with relapsed/refractory T-ALL: A phase I trialLiping Zhao, Chuo Li, Shiyu Zuo, et al.
International Journal of Radiation Oncology, Biology, Physics|April 3, 2025
Differentiation Stage Predicts Radiosensitivity in Mesenchymal-Like Pancreatic CancerTingshi Su, Xinjian Yu, Mojtaba Hoseini-Ghahfarokhi, et al.
Nature Communications|July 22, 2024
C-JUN overexpressing CAR-T cells in acute myeloid leukemia: preclinical characterization and phase I trialShiyu Zuo, Chuo Li, Xiaolei Sun, et al.
Pageof 6